Revenue increased 47% to 2.8 million euros, compared with 1.9 million euros in the first quarter of 2019. All of the revenue came from the company's imaging contract research organization (iCRO) business, which provides software and services for medical image management in oncology clinical trials.
Median also reported a backlog of 44.4 million euros in the first quarter, compared with a backlog of 38.2 million euros at the end of the 2019 calendar year. The 2020 first-quarter backlog was fueled by increases in Europe and China, with China accounting for 46% of the first-quarter total, despite clinical trial delays in the country due to the novel coronavirus.
Copyright © 2020 AuntMinnieEurope.com